Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Cancer Pain 2Medication Adherence 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gastrointestinal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1

Interventions

Cyclophosphamide 82Imatinib Mesylate 81fludarabine phosphate 67fludarabine 62Whole-Body Irradiation 55Mycophenolic Acid 54Tacrolimus 42nilotinib 40Busulfan 39Dasatinib 32Cyclosporine 30Peripheral Blood Stem Cell Transplantation 28thymoglobulin 25Melphalan 25Thiotepa 24Cytarabine 24Granulocyte Colony-Stimulating Factor 23Antilymphocyte Serum 23Methotrexate 21Filgrastim 21Stem Cell Transplantation 20ponatinib 16Sirolimus 16sargramostim 14Cord Blood Stem Cell Transplantation 13Rituximab 11Cyclosporins 11Clofarabine 11venetoclax 10peginterferon alfa-2b 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Pharmaceutical Services × Clear all
NCT03090477 2019-04-05

Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients

UCSI University

Phase NA Completed
129 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication Adherence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡